SCHEDULE: Trails Edge Capital Discloses 8.7% Stake in Immunic

Trails Edge Capital Partners, LP, along with its affiliates, has reported a passive beneficial ownership of 8.7% in Immunic, Inc., totaling 11,454,000 common shares.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai collectively reported beneficial ownership of 11,454,000 common shares of Immunic, Inc.
• This represents an 8.7% stake in the company's outstanding common stock.
• The ownership includes 5,727,000 shares underlying pre-funded warrants and 5,727,000 shares underlying warrants, all held directly by Trails Edge Biotechnology Master Fund, LP.
• The ownership percentage is based on 120,284,724 shares of Common Stock outstanding as of November 11, 2025, as reported by Immunic, Inc. in its Form 10-Q.
• The filing indicates a passive investment intent, not for changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies significant institutional confidence in Immunic, Inc. without indicating any immediate intent to influence control, suggesting stability.

Positives

• Significant institutional investment by Trails Edge Capital Partners, LP and its affiliates, indicating confidence in Immunic, Inc.
• The investment is passive, suggesting stability and no immediate intent to influence company control.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Immunic, Inc.'s future performance or operations, as it is solely an ownership disclosure.

Management Comments

• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Immunic, Inc.

Industry Context

StockSavvy.ai notes that significant institutional ownership, particularly from specialized funds like Trails Edge Biotechnology Master Fund, LP, can signal a vote of confidence in a company's long-term prospects within the biotechnology sector. Such filings are common for passive investors crossing the 5% ownership threshold.

Comparison to Industry Standards

• StockSavvy.ai observes that an 8.7% stake is a substantial position for an institutional investor in a publicly traded biotechnology company. While specific comparable companies or projects are not detailed in this filing, such a stake often places the investor among the top shareholders, aligning with typical institutional investment strategies in growth-oriented sectors like biotech.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling market confidence and stability.
• Company Management: The passive nature of the investment suggests no immediate pressure for strategic or operational changes from this investor.

Key Dates

Recommendation

While this filing primarily discloses a significant passive ownership stake by an institutional investor, it doesn't provide enough operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The substantial 8.7% stake by Trails Edge Capital Partners, LP and its affiliates suggests a long-term, confident position in Immunic, Inc., which could be seen as a positive signal for existing shareholders. Therefore, a 'hold' recommendation is appropriate, awaiting further operational updates from Immunic, Inc. itself.

Keywords

Immunic Inc, Trails Edge Capital, Trails Edge Biotechnology, Ortav Yehudai, Schedule 13G, beneficial ownership, institutional investment, common shares, warrants, pre-funded warrants, biotechnology, passive investment